Evidence map›Paper›PMID 28698285›Full record

ArticleThe Journal of experimental medicine2017

Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL.

Arturo I Machuca-Parra, Alexander A Bigger-Allen, Angie V Sanchez, Anissa Boutabla, Jonathan Cardona-Vélez, Dhanesh Amarnani, Magali Saint-Geniez, Christian W Siebel, Leo A Kim, Patricia A D'Amore and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Pericytes in the disease spotlight.Trends in cell biology · 2024
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 3 countries.

Arturo I Machuca-ParraSchepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA.
Alexander A Bigger-AllenSchepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA.
Angie V SanchezSchepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA.
Anissa BoutablaSchepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA.ORCID http://orcid.org/0000-0001-6408-4555
Jonathan Cardona-VélezSchepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA.ORCID http://orcid.org/0000-0002-4382-9391
Dhanesh AmarnaniSchepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA.ORCID http://orcid.org/0000-0002-0678-768X
Magali Saint-GeniezSchepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA.
Christian W SiebelDepartment of Discovery Oncology, Genentech, Inc., South San Francisco, CA.ORCID http://orcid.org/0000-0003-4333-3756
Leo A KimSchepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA.ORCID http://orcid.org/0000-0001-9106-6416
Patricia A D'AmoreSchepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA patricia_damore@meei.harvard.edu.ORCID http://orcid.org/0000-0001-9652-8974
Joseph F Arboleda-VelasquezSchepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA joseph_arboleda@meei.harvard.edu.ORCID http://orcid.org/0000-0002-3192-9117
Massachusetts Eye and Ear Infirmary · US

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Sunil K Chauhan · 1985 to 2026
$25.5M
Mass Eye and Ear-Vision Clinical Scientist Development ProgramK12EY016335 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Reza Dana · 2004 to 2026
$12.3M
THE ROLE OF MICROVASCULAR CELLS IN NEOVASCULARIZATIONR01EY005318 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI D'AMORE, PATRICIA ANN · 1985 to 2015
$6.4M
Notch and TGF-beta in the Control of Retinal Vascular IntegrityR00EY021624 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI ARBOLEDA-VELASQUEZ, JOSEPH · 2014 to 2016
$736k
Vasculogenesis in Thyroid Eye DiseaseR21EY027061 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI KIM, LEO A · 2016 to 2017
$542k
Exploring the Role of Aging in Cerebral Ischemic Small Vessel Disease Using Notch3 Mutant MiceUH2NS100121 · NINDS · SCHEPENS EYE RESEARCH INSTITUTE · PI ARBOLEDA-VELASQUEZ, JOSEPH · 2016 to 2017
$277k
NEI NIH HHS K12 EY016335NEI NIH HHS P30 EY003790NEI NIH HHS R00 EY021624NEI NIH HHS R01 EY005318NEI NIH HHS R21 EY027061NINDS NIH HHS UH2 NS100121
6 · The paper itself

Abstract

Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a neurological syndrome characterized by small vessel disease (SVD), stroke, and vascular cognitive impairment and dementia caused by mutations in

Indexed as

AnimalsAntibodiesCADASILDisease Models, AnimalFemaleMaleMice, Inbred C57BLMice, KnockoutMice, TransgenicMuscle, Smooth, VascularPericytesReceptor, Notch3Signal TransductionAntibodiesNotch3 protein, mouseReceptor, Notch3

Identifiers

PMID28698285
PMCPMC5551569
OpenAlexW2734751202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.